Biogen Posts Third Straight Quarter of Growth as Apellis and Spinraza Carry the Line
- Biogen's third-quarter revenue was $2.8 billion, ahead of the roughly $2.6 billion expected; its growth portfolio, including Leqembi and Spinraza, rose 49%.
- Spinraza benefited from faster patient switching to the high-dose regimen, and Leqembi sales rose 67%, with US sales a little over half of the total.
- Syfovre and Empaveli from the $5.6 billion Apellis deal brought in $243 million, above consensus in the first full quarter.
💡 Points Based on public reports
The Apellis purchase is doing what an acquirer wants: it bought revenue immediately and bridges the decline of older franchises. But acquired IPR&D pushed the adjusted result into a loss, and analysts say the stock now trades on clinical catalysts over the next year rather than on earnings. Growth is real; pipeline readouts decide the story.
Biogen notches 3rd straight quarter of growth thanks to newer products, Apellis ↗